Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Telmisartan in Preventing Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients

NCT07370506 is registered in ClinicalTrials.gov with Tanta University as lead sponsor.

NCT NCT07370506
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07370506 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Telmisartan in Preventing Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients
Lead sponsor
Tanta University
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
February 28, 2026
Completion date
February 28, 2027
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, doxorubicin induced cardiomyopathy